As the world awaited results from the US presidential election, Pfizer
(NYSE:PFE) scored its own victory Tuesday with the approval
of a pill that treats rheumatoid arthritis.
With Xeljanz, Pfizer is believed to have a potential blockbuster -- a drug that potentially generates a few billion dollars a year in revenue, according to Wall Street analysts. Speculation by analysts also focuses on how much market share Pfizer can take from existing injected rheumatoid arthritis drugs, including Amgen’s
(NASDAQ:AMGN) Enbrel, Johnson & Johnson’s
(NYSE:JNJ) Remicade and the big gorilla, Abbott Laboratories’
(NYSE:ABT) Humira. (Pfizer is unwinding a sales partnership with Amgen for Enbrel.)
Humira is poised to become the world’s biggest-selling drug.
RBC Capital Markets analyst Glenn Novarro predicts Humira sales will top more than $9 billion this year and more than $10 billion in 2013. He does not plan to immediately change his forecast for the drug based on the approval of Pfizer’s Xeljanz.
“We do not expect the convenience benefit of an oral to outweigh Humira's long-term efficacy and safety track record,” Novarro says in a note to clients Wednesday. He has a buy rating on Abbott’s stock.
Indeed, Pfizer’s drug carries a number of warnings, including risk of infections, tuberculosis and cancer. As part of its drug approval, Pfizer is required to carry out a plan to evaluate and mitigate the risks to patients. At almost $25,000 a year, the Pfizer drug is priced at a slight discount to the injected therapies.
Xeljanz, also known as tofacitinib, is part of a class of drugs known as JAK inhibitors. The Pfizer drug is approved by the Food and Drug Administration to treat patients with moderate to severe rheumatoid arthritis who are intolerant or can’t be treated with an older drug, methotrexate.
Other companies are studying JAK inhibitors. Eli Lilly
(NYSE:LLY) and Incyte
(NASDAQ:INCY) are studying a drug to treat rheumatoid arthritis. Incyte’s JAK inhibitor Jakafi was approved by the FDA last year for the blood cancer myelofibrosis. YM Biosciences
(NYSEAMEX:YMI) is in the early stages of testing a JAK inhibitor for inflammatory diseases, including rheumatoid arthritis, and cancer. The drugs are designed to inhibit a family of enzymes known as Janus kinases, which are linked to certain diseases.
Considered a promising new therapy, Pfizer’s drug is approved at a crucial point for the company. For years, Pfizer relied on the cholesterol drug Lipitor, which has been the world’s top-selling drug until recent generic competition. Pfizer desperately needs new blockbusters to fill the void of Lipitor and other older drugs.
Shares of Pfizer fell about 1% to $24.30 in morning trading Wednesday as the broader market also dipped. The stock is up more than 12% in 2012. Abbott, which plans to break into two separate companies later this year, fell almost 2% to $63.77. The company’s shares are up more than 13% this year. Incyte gained 1% to $17.89 and Lilly fell 1% to $48.43.
No positions in stocks mentioned.
The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.
Copyright 2011 Minyanville Media, Inc. All Rights Reserved.